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Abstract
Information on the species causing Candida peritonitis, their in vitro susceptibility, antifungal strategies in this setting and patient outcome
is still scarce. AmarCand was a prospective, non-interventional study in 271 adult intensive-care unit (ICU) patients with proven invasive
Candida infection who received systemic antifungal therapy (France, 2005–2006). Of these ICU patients, 93 (median age 65 years, simpli-
ﬁed acute physiology score II 52) had Candida peritonitis, including 73 nosocomial peritonitis, 53 concomitant bacterial peritoneal infec-
tions and 26 candidaemias. Candida species were C. albicans (n = 63/108 isolates, 58%), C. glabrata (n = 22, 20%), C. krusei (n = 9),
C. kefyr (n = 5), C. parapsilosis (n = 3), C. tropicalis (n = 3), C. ciferii (n = 2) and C. lusitaniae (n = 1). Of tested isolates, 28% were ﬂuco-
nazole-resistant or susceptible dose-dependent (C. albicans 3/32, C. glabrata 9/14, C. krusei 4/4). Empiric antifungal treatment was started
1 day (median) after peritonitis diagnosis, with ﬂuconazole (n = 72 patients), caspofungin (n = 12), voriconazole (n = 3), amphotericin B
(n = 2), or a combination (n = 4). Following susceptibility testing, empiric antifungal treatment was judged inadequate in 9/45 (20%)
patients and modiﬁed in 30 patients (ﬂuconazole was replaced by caspofungin (n = 14) or voriconazole (n = 4)). Mortality in ICU
was 38% (35/93) and was not inﬂuenced by type of Candida species, ﬂuconazole susceptibility, time to treatment, candidaemia, noso-
comial acquisition, or concomitant bacterial infection. No speciﬁc factors for death were identiﬁed. In summary, a high proportion of
ﬂuconazole-resistant or susceptible dose-dependent strains was cultured. These results conﬁrm the high mortality rates of Candida
peritonitis and plead for additional investigation in this population. Antifungal treatment for severe cases of Candida peritonitis in ICU
patients remains the standard care.
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Introduction
Invasive Candida infections are associated with high mortality,
especially in intensive-care units (ICUs). Both rapid initiation
of appropriate antifungal therapy and efﬁcient source control
are essential for their treatment and have been shown to
reduce mortality [1–3]. Candida peritonitis is frequent, repre-
senting up to 71% of invasive Candida infections in surgical
ICUs [4–6]. In previous French single-centre studies, the inci-
dence of Candida was 13–33% in postoperative peritonitis
[7–9] and 7–32% in community-acquired peritonitis [7,9,10].
However, information on the species causing Candida perito-
nitis, their in vitro susceptibility, antifungal treatments and
patient outcome is still scarce. Recently, we conducted in
the ICU setting a prospective study (‘AmarCand’) on invasive
Candida infections [11]. We describe here the detailed epide-
miology, management and prognosis in the subgroup of
patients with Candida peritonitis.
ª2010 The Authors
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE MYCOLOGY
Patients and Methods
Study design and patients
‘AmarCand’ was a prospective, multicentre, French observa-
tional study involving adult ICU patients with invasive Can-
dida infection requiring a systemic antifungal therapy [11].
Criteria used for diagnosis were those proposed by the Inva-
sive Fungal Infection Group of the European Organization
for Research and Treatment of Cancer [12]. In accordance
with French law, approval of an ethics committee was not
required. However, all patients gave informed consent to
participate and procedures were in accordance with the
Helsinki Declaration. A scientiﬁc committee (the authors)
independently designed the study, and reviewed the data.
Clinical and mycological data
For each episode of Candida peritonitis, demographic charac-
teristics, underlying diseases and severity of illness were
compared with the other patients in the Amarcand cohort.
Empiric antifungal treatment, interventions associated with
antifungal treatment and risk factors for death were assessed
in cases of Candida peritonitis [11].
Peritonitis was diagnosed on the basis of macroscopic
ﬁndings and direct examination or positive culture for
Candida of the peritoneal ﬂuid collected during operation.
Candidaemia was deﬁned by at least one positive blood
culture. Candida peritonitis was considered as nosocomial if
diagnosed ‡48 h after hospitalization or community-acquired
(<48 h).
Identiﬁcation of Candida isolates and measures of their
in vitro antifungal susceptibility were performed in the micro-
biology laboratory of each hospital as previously described
[11]. Isolates were classiﬁed as susceptible (S), susceptible-
dose-dependent (SDD) or resistant (R) to antifungals accord-
ing to CLSI interpretative categories (http://www.clsi.org).
Empiric treatment was classiﬁed as inadequate if at least
one Candida strain was resistant or SDD (ﬂuconazole
<10 mg/kg/day) to the antifungal administered and adequate
if all Candida isolates were found susceptible to at least one
antifungal given.
Statistics
Statistical analyses were performed using SAS 9.1 (SAS
Institute Inc., Cary, NC, USA). Variables were expressed as
median values and ranges for numerical variables and as fre-
quencies and percentages for categorical variables. Groups
were compared using the Wilcoxon, chi-square or Fisher’s
exact tests where appropriate. Statistical signiﬁcance was
accepted at the 5% level.
Results
Patient characteristics and episodes of infection
Among the 271 patients recruited between October 2005
and May 2006 in the ‘AmarCand’ cohort [11], the present
study focused on the 93 evaluable patients treated for nos-
ocomial peritonitis (n = 73) and community-acquired perito-
nitis (n = 20). The clinical characteristics of these patients
with Candida peritonitis were compared with those of the
remaining 178 patients without peritonitis. There were
increased proportions of immunosuppression in the absence
of peritonitis and increased proportions of solid tumour
and concomitant bacterial infections in Candida peritonitis
(Table 1).
In patients with Candida peritonitis, the median length of
stay in hospital before admission onto ICU was 3 days. Con-
comitant candidaemia was documented in 26 (28%) patients.
The median time from surgery to collection of the ﬁrst posi-
tive sample was 9 days. The time from admission onto ICU
to the ﬁrst positive blood culture was £5 days in 14/26
(54%) patients. Candidaemic patients did not differ from
other patients, except for a higher sepsis-related organ fail-
ure assessment score (Table 1). Candida-positive specimens
were obtained from other sites in 23 patients (skin/soft tis-
sues (n = 3), urinary tract (n = 9), respiratory tract (n = 8),
abdomen (n = 9), venous access (n = 3) and mucosa
(n = 4)).
Patients with nosocomial infection were younger than
those with community-acquired infections (median 63 vs
75 years, respectively, p 0.02) and had received more anti-
bacterial therapy (48% vs 15%, respectively, p 0.01). In the
group of nosocomial peritonitis, the time from hospitaliza-
tion to admission onto ICU and the time from central
venous catheter insertion to onset of Candida infection
were longer than in community-acquired infections
(median 5 vs 0.5 days, p <0.001; and 6 vs 0 days, p <0.001,
respectively).
Direct mycological examination of the peritoneal ﬂuid
was carried out in 78 patients and peritoneal ﬂuid culture
was performed in 90 patients. In addition to fungi, 103
bacteria were identiﬁed in the peritoneal ﬂuid of 53
patients with up to three different species per patient.
The most frequent organisms were Enterobacteriaceae
(n = 47), enterococci (n = 16) and anaerobes (n = 15).
Two of these 53 patients also had concomitant bactera-
emia. There were no signiﬁcant differences of clinical
characteristics between patients with concomitant bacterial
infection and patients with isolated Candida peritonitis
(data not shown).
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Mycological data
In the 93 episodes of peritonitis, 108 Candida isolates were
identiﬁed (Fig. 1). The proportion of non-albicans Candida
spp. was 45% (38/85 isolates) in nosocomial infections, 30%
(7/16 isolates) in community-acquired infections, 45% (28/62
isolates) in patients with concomitant bacterial infections
and 37% (17/29 isolates) in those with isolated Candida
infections. Two different Candida species were found in 15
patients, mainly C. albicans associated with C. glabrata
(n = 7).
In the 26 patients with candidaemia, the same species
were identiﬁed from blood cultures and peritoneal ﬂuid sam-
ples (Fig. 1). In the 33 patients with solid tumours, C. albicans
was found in 22, C. glabrata in eight, C. kefyr in four, C. krusei
in two, C. tropicalis in one and C. ciferii in one. In the eight
patients with previous exposure to azole agents, C. albicans
was found in four, C. glabrata in four, and C. krusei in one.
In vitro susceptibility to ﬂuconazole was determined for
60/108 isolates and 17/60 (28%) were ﬂuconazole-R or SDD
Candida isolates (Fig. 2). The proportion of patients with
peritonitis caused by at least one ﬂuconazole-R or SDD
Candida strain was 17% (16/93) overall and was higher when
candidaemia was concomitant (35% vs 10% without candida-
emia, p 0.01).
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FIG. 1. Distribution of the Candida species identiﬁed within the peri-
toneal ﬂuid (open boxes) and blood cultures (closed boxes)
expressed as number of isolates.
TABLE 1. Clinical characteristics of the population of the AmarCand study with or without Candida peritonitis on admission
in Intensive Care Unit and patients with peritonitis with and without candidemia, expressed as median (range) values or num-
bers (%) of patients
Characteristic
AmarCand study Patients with Candida peritonitis
Total study
population
(n = 271)
Patients without
peritonitis
(n = 178)
Patients with
Candida
peritonitis (n = 93) pa
Patients with
candidaemia
(n = 26)
Patients without
candidaemia
(n = 67) pb
Age (years) 64 (18–90) 64 (18–87) 65 (21–90) 0.3 61 (35–79) 67 (21–90) 0.5
Male gender 163 (60) 113 (64) 50 (54) 0.1 14 (54) 36 (54) 1
Type of infection 0.06 0.6
Community-acquired infection 43 (16) 23 (13) 20 (22) 4 (15) 16 (24)
Nosocomial infection 228 (84) 155 (87) 73 (78) 22 (85) 51 (76)
Underlying diseasec 0.6 0.8
Non-fatal 129 (47) 81 (46) 48 (52) 12 (46) 36 (54)
Ultimately fatal 113 (42) 78 (44) 35 (38) 11 (42) 24 (36)
Rapidly fatal 29 (11) 19 (11) 10 (11) 3 (12) 7 (10)
Invasive mechanical ventilation 205 (76) 129 (73) 76 (82) 0.1 19 (73) 57 (85) 0.2
Central venous catheter 247 (91) 163 (92) 84 (90) 0.7 22 (85) 62 (93) 0.3
Implantable drug delivery device 15 (6) 11 (6) 4 (4) 0.5 1 (4) 3 (5) 1
Urinary catheter 235 (87) 152 (85) 83 (89) 0.4 23 (89) 60 (90) 1
Prior antibiotherapyd 160 (59) 122 (69) 38 (41) <0.001 11 (42) 27 (40) 1
Immunosuppression 57 (21) 47 (26) 10 (11) 0.003 2 (8) 8 (12) 0.7
Chronic renal failure 46 (17) 35 (20) 11 (12) 0.1 1 (4) 10 (15) 0.2
Type 1 diabetes mellitus 29 (11) 24 (14) 5 (5) 0.04 0 (0) 5 (8) 0.3
Neutropenia (<500/mm3) 18 (7) 16 (9) 2 (2) 0.03 1 (4) 1 (2) 0.5
Solid tumour 71 (26) 38 (21) 33 (36) 0.03 9 (35) 24 (36) 1
Haematological malignancy 21 (8) 17 (10) 4 (4) 0.2 1 (4) 3 (5) 1
Active intravenous drug use 3 (1) 2 (1) 1 (1) 1 1 (4) 0 (0) 0.3
Body temperature >38.2Ce 145 (54) 101 (57) 44 (47) 0.2 12 (46) 32 (48) 1
SAPS II score 49 (6–121) 48 (6–121) 52 (15–94) 0.6 56 (19–83) 50 (15–94) 0.2
SOFA score 9 (1–22) 9 (1–22) 9 (1–22) 0.7 12 (1–17) 9 (1–22) 0.04
Concomitant bacterial infection 75 (28) 22 (12) 53 (57) <0.001 12 (46) 41 (61) 0.2
Prior exposure to azole agents 31 (11) 23 (13) 8 (9) 0.3 3 (12) 5 (7) 0.7
Prior colonization with ﬂuconazole-R strains 7 (3) 2 (1) 5 (5) 0.05 2 (8) 3 (4) 0.6
SAPS, simpliﬁed acute physiology score; SOFA, sepsis-related organ failure assessment.
aComparison between patients without peritonitis and with Candida peritonitis in the AmarCand study cohort.
bComparison between patients with and without candidaemia in the subpopulation of patients with Candida peritonitis.
cClassiﬁcation of McCabe and Jackson [28].
dFor >5 days in the past month.
eAt onset of the episode of invasive Candida infection.
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In the eight patients with previous exposure to azole
agents, ﬁve of the nine Candida isolates were tested for
ﬂuconazole sensitivity and four of them (three C. glabrata
and one C. albicans) were ﬂuconazole-R in three patients;
one patient carried a ﬂuconazole-R C. glabrata and a ﬂuco-
nazole-R C. albicans. In the ﬁve patients with previous coloni-
zation with a ﬂuconazole-R strain, four of seven Candida
isolates were tested for ﬂuconazole sensitivity and two of
them (C. krusei and C. ciferii) were ﬂuconazole-R or SDD in
two patients with polyfungal infection.
Antifungal treatment
In all cases, empiric antifungal treatment was initiated a med-
ian of 1 day after the ﬁrst positive sample was drawn (>1 day
in 36/91 (40%) patients) without signiﬁcant difference according
to candidaemia, nosocomial/community-acquired infection,
surgery, or concomitant bacterial infection. Monotherapy was
administered in 89/93 (96%) patients using ﬂuconazole (med-
ian dose 9 mg/kg/day; n = 72), caspofungin (n = 12), vorico-
nazole (n = 3), amphotericin B deoxycholate (n = 1), and
liposomal amphotericin B (n = 1), whereas combinations
were prescribed in the other four patients (Table 2).
Before species identiﬁcation, the antifungal treatment was
modiﬁed in seven patients (Table 2), because of clinical wors-
ening in four patients and due to adverse events in three
patients. Fluconazole was replaced by either caspofungin
(n = 5) or voriconazole (n = 2).
Three days (median) after identiﬁcation of the causative
Candida and susceptibility testing, antifungal treatment was
modiﬁed in 30 patients (nine with candidaemia) from the
empiric treatment (Table 2). The main reasons were species
identiﬁcation (n = 19), susceptibility results (n = 15) and clin-
ical reasons (n = 12). The most frequent modiﬁcation was
the replacement of a single agent by another one (n = 26),
most often ﬂuconazole by caspofungin (n = 14) or voricona-
zole (n = 4) (Table 2). In the nine patients with candidaemia,
the most frequent modiﬁcation was replacement of ﬂucona-
zole by caspofungin (n = 3) or voriconazole (n = 1).
According to the susceptibility results, empiric antifungal
treatment appeared as inadequate in 9/45 (20%) patients. In
these patients, ﬂuconazole was replaced by caspofungin
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FIG. 2. Rate of ﬂuconazole-resistant or susceptible-dose-dependent
Candida strains expressed as proportions of tested isolates.
TABLE 2. Empiric antifungal treatment, subsequent changes and outcome observed in the 93 studied patients
Empiric antifungal treatment
Early change of
antifungal treatment
Changes at the time of
identiﬁcation and susceptibility testing
Survivors/No.
of patients
Fluconazole (n = 72) No change (n = 67) No change (n = 51) 33/51
Fluconazole + liposomal
amphotericin B (n = 1)
1/1
Amphotericin B deoxycholate (n = 2) 2/2
Caspofungin (n = 3) Caspofungin (n = 14) 8/14
Voriconazole (n = 2) Voriconazole (n = 4) 2/4
Caspofungin (n = 12) No change (n = 12) No change (n = 8) 4/8
Voriconazole (n = 1) 2/4
Fluconazole (n = 2)
Caspofungin + liposomal
amphotericin B (n = 1)
Voriconazole (n = 3) No change (n = 2) No change (n = 1) 0/1
Caspofungin (n = 1) 1/1
Caspofungin (n = 1) Fluconazole (n = 1) 1/1
Amphotericin B deoxycholate (n = 1) No change (n = 1) No change (n = 1) 1/1
Liposomal amphotericin B (n = 1) No change (n = 1) Caspofungin (n = 1) 1/1
Fluconazole + caspofungin (n = 3) No change (n = 2) No change (n = 1) 0/1
Caspofungin (n = 1) Caspofungin (n = 2) 1/2
Fluconazole + amphotericin
B deoxycholate (n = 1)
No change (n = 1) No change (n = 1) 0/1
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(n = 5) or amphotericin B deoxycholate (n = 1), or was
unchanged (n = 1); voriconazole was replaced by caspofungin
(n = 1); caspofungin plus ﬂuconazole was replaced by caspo-
fungin alone (n = 1). In two patients with SDD C. glabrata
who were initially receiving high doses of ﬂuconazole
(>10 mg/kg), the ﬂuconazole was changed to caspofungin and
voriconazole.
During the hospital stay, intravascular devices were
removed in 14 patients 4 days (median) after the ﬁrst posi-
tive sample was drawn, and such removal was more frequent
in patients with candidaemia than in those without (9/16
(56%) vs 5/42 (12%), p 0.001). Additional drainage of persis-
tent intra-abdominal abscesses was performed in 45 patients.
These patients less often had candidaemia than the 48
patients who did not need the procedure (7/45 (16%) vs 19/
29 (40%), p 0.012).
Outcome
The median duration of antifungal treatment was 20 days for
survivors and 12 days for non-survivors. The case fatality
ratio was 38% (35/93) in ICU and 41% (38/92) at discharge
from hospital. The species-associated case fatality ratio in
ICU was similar for C. albicans (22/63, 35%), C. glabrata (7/22,
32%), C. krusei (3/9, 33%) and C. tropicalis (1/3, 33%). It was
higher with C. kefyr (4/5, 80%) and C. ciferrii (2/2, 100%) and
null with C. parapsilosis (0/3).
There were no signiﬁcant differences between patients
with C. albicans exclusively and patients with non-albicans
species (35% vs 41%, respectively), or between patients who
carried one or more ﬂuconazole-R or SDD strain, those
infected exclusively with ﬂuconazole-S strains, and those with
undetermined ﬂuconazole susceptibility (44% vs 42% vs
42%), or between patients with isolated Candida peritonitis
and those with concomitant bacterial infection (45% vs 36%).
The comparison of clinical characteristics between survi-
vors and non-survivors shows the role of underlying disease
and severity of infection in the prognosis and a trend toward
increased mortality in patients with nosocomial peritonitis
(Table 3). Survivors did not differ signiﬁcantly from non-sur-
vivors with regard to the nature of empiric antifungal treat-
ment, whether it was adequate or not according to the
susceptibility test results, the time from peritoneal ﬂuid col-
lection and the initiation of empiric treatment, and the time
from sample collection and initiation of adequate treatment.
Discussion
To our knowledge, this paper represents the ﬁrst large-scale
description of therapeutic management of intra-abdominal
Candida infections whereas previous studies addressed mainly
diagnosis and prognosis issues [8,9,13–17]. Interestingly, our
data demonstrate that patients with Candida peritonitis differ
from those with other invasive Candida infections in many
aspects, including underlying diseases. When this observa-
tional study was initiated, the 2003 Infectious Diseases Soci-
ety of America (IDSA) guidelines for complicated intra-
abdominal infections [18] suggested that antifungal therapy
was unnecessary in patients with acute perforations of the
gastrointestinal tract, unless patients had recently received
immunosuppressive therapy or had postoperative or recur-
rent intra-abdominal infection. In the current study, the need
to treat Candida peritonitis was not addressed and was prob-
ably not a source of debate. When compared with recent
cohorts of Candida peritonitis, our patients had a higher
degree of severity and a ﬁve- to six-fold increased frequency
of candidaemia [15,19]. Almost half of our patients had pure
Candida peritonitis, whereas this characteristic is usually
reported in 4–27% of patients [15,19]. These features could
explain why our patients received rapidly systemic antifungal
treatment.
TABLE 3. Major clinical characteristics of 93 patients with
Candida peritonitis according to the outcome at discharge
from Intensive Care Unit, expressed as median (range) val-
ues or numbers (%) of patients
Characteristic
Survivors
(n = 58)
Non-survivors
(n = 35) p
Age (years) 65 (21–90) 65 (47–89) 0.6
Male gender 30 (52) 20 (57) 0.7
Underlying diseasea 0.004
Non fatal 37 (64) 11 (31)
Ultimately fatal 18 (31) 17 (49)
Rapidly fatal 3 (5) 7 (20)
Type of infection 0.07
Community-acquired infection 16 (28) 4 (11)
Nosocomial infection 42 (72) 31 (89)
Invasive mechanical ventilation 45 (78) 31 (89) 0.3
Central venous catheter 51 (88) 33 (94) 0.5
Urinary catheter 50 (86) 33 (94) 0.3
Implantable drug delivery device 1 (2) 3 (9) 0.1
Prior antibiotherapyb 21 (36) 17 (49) 0.3
Immunosuppression 6 (10) 4 (11) 1
Chronic renal failure 4 (7) 7 (20) 0.09
Type 1 diabetes mellitus 1 (2) 4 (11) 0.06
Neutropenia (<500/mm3) 1 (2) 1 (3) 1
Solid tumour 21 (36) 12 (34) 1
Haematological malignancy 1 (2) 3 (1) 0.2
Active intravenous drug use 1 (2) 0 (0) 1
Body temperature >38.2Cc 29 (50) 15 (43) 0.2
Baseline SAPS II score 47 (19–94) 56 (15–82) 0.01
Baseline SOFA score 8 (1–18) 11 (2–22) 0.001
Concomitant candidaemia 16 (28) 10 (29) 0.9
Concomitant bacterial infection 36 (62) 17 (49) 0.3
Prior exposure to azole agents 4 (7) 4 (11) 0.5
Prior colonization with
ﬂuconazole-R strains
4 (7) 1 (3) 0.6
SAPS, simpliﬁed acute physiology score; SOFA, sepsis-related organ failure
assessment.
aClassiﬁcation of McCabe and Jackson [28].
bFor >5 days in the past month.
cAt onset of the episode of invasive Candida infection.
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This highly selected population, the subgroup analysis and
the observational design of the study could be considered as
poorly representative of Candida peritonitis in reality. More-
over, several speciﬁcities of intra-abdominal infections (loca-
tion of infection, type of surgery, adequacy of source
control) were not assessed. This point is a limitation of the
value of our data. However, in the absence of therapeutic
data in the literature, we consider that our data provide a
unique, up-to-date picture of Candida peritonitis in ICU,
addressing important issues for clinicians such as selection of
treatment, early changes, adequacy, or de-escalation.
In our study, C. albicans was the predominant species iso-
lated followed by C. glabrata. This is consistent with other
reports on intra-abdominal Candida infection in European
ICUs [8,15,16,19,20]. However, we found a 42% rate of
non-albicans species compared with 17–34% in the litera-
ture [8,15,16,19,20]. Candida krusei was the third most fre-
quent isolate (8%) whereas this organism has rarely been
reported [19]. Emergence of C. krusei and C. glabrata from
patients with previous exposure to azole agents has not
been previously reported in patients with Candida peritoni-
tis. The proportion of strains with reduced susceptibility to
ﬂuconazole was high, 9% for C. albicans and 64% for C. glab-
rata, compared with 0% and 0–80%, respectively, in previ-
ous studies in intra-abdominal infection [15,16,19]. These
observations, coupled with the increased use of ﬂuconazole
prophylaxis [16,20], could lead to consideration of an
increased empiric use of echinocandins in critically ill
patients with peritonitis, as recently suggested by the
revised IDSA guidelines [21].
We did not observe any superiority of any regimen. This is
not a surprise considering the observational design of the
study. Controlled studies assessing the efﬁcacy/beneﬁt of anti-
fungal agents are needed in this indication, in particular in ICU
patients. Among the studies carried out in invasive Candida
infection [22–27], none has been dedicated to intra-abdominal
infection. Among the randomized controlled trials published in
the last decade, only 62 patients with peritonitis were studied
in three trials gathering a total of 1365 patients with invasive
Candida infection. No drug ever demonstrated superiority
compared with other antifungal agents. In 16 patients included
in the study of Mora-Duarte et al. [23], the authors reported
success rates of 87.5% with amphotericin B and 100% with ca-
spofungin. Among 28 patients, Kuse et al. [22] recorded 72.7%
success with liposomal amphotericin B and 82.4% with mica-
fungin, whereas Pappas et al. in 18 patients [24] observed 40%
success with caspofungin and 66.7% and 57.1% with micafungin
100 mg and 150 mg daily, respectively.
In the literature, the case fatality ratio in Candida peritonitis
varies from 25% to 60% in ICUs [8,15,16,19,20]. Several risk
factors associated with death in Candida peritonitis have been
described [15,19]. Isolation of Candida species in peritoneal
specimens seems to be an independent risk factor for death in
nosocomial [19] and postoperative peritonitis [9]. In the pres-
ent study, mortality rate is in the medium range (38%) without
any speciﬁc risk factors for death except those related to
underlying diseases and severity of infection. However, our
observations should be considered cautiously because this
observational study was not designed to address the impact of
initial antifungal treatment. Our observations are in line with
the revised IDSA recommendations of antifungal therapy for
severe cases of Candida peritonitis [21]. Fluconazole was the
ﬁrst-line treatment in most of our cases. Based on these guide-
lines, a dramatic increase in the prescription of echinocandins
could be expected if this survey were initiated today.
In conclusion, a high proportion of ﬂuconazole-R or SDD
strains was cultured leading to discussion of ﬁrst-line treat-
ment of Candida peritonitis. Mortality was high despite early
treatment and no speciﬁc factor was associated with death.
Improvements in the descriptive criteria for identiﬁcation of
non-albicans species and ﬂuconazole-R or SDD strains are
required. For the moment, antifungal treatment for severe
cases of Candida peritonitis in ICU patients remains the stan-
dard care.
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Appendix
The ‘AmarCand’ Study Group (ICU physicians): Drs. Allaou-
chiche (Lyon), Baldesi (Aix-en-Provence), Baudin (Paris),
Blondeau (Roubaix), Bonadona (La Tronche), Braud (Rouen),
Bret (Lyon), Brocas (Evry), Bruneel (Versailles), Canevet
(Armentie`res), Carlet (Paris), Chastagner (Chamberry),
Courte (Saint-Brieuc), Diconne (Saint Etienne), Dube
(Angers), Dumenil (Clamart), Dupont (Amiens), Durand
(Grenoble), Fangio (Poissy), Fieux (Paris), Fleureau (Pessac),
Fulgencio (Paris), Gally (Mulhouse), Garnaud (Orle´ans), Ga-
rot (Tours), Gilhodes (Cre´teil), Gouin (Rouen), Jospe (Saint
Etienne), Kaidomar (Fre´jus), Kherchache (Agen), Lacherade
(Poissy), Lamia (Le Kremlin-Biceˆtre), Lasocki (Paris), Launoy
(Strasbourg), Le Guillou (Paris), Lefrant (Nıˆmes), Lepoutre
(Lomme), Leroy (Tourcoing), Mahe (Nantes), Mathonnet
(Paris), Mercat (Angers), Mourvillier (Paris), Navellou (Bes-
anc¸on), Obadia (Montreuil), Perrigault (Montpellier), Poussel
(Metz), Renard (La Roche sur Yon), Robert (Poitiers), Saliba
(Villejuif), Santre´ (Annecy), Seguin (Rennes), Valentin (Bes-
anc¸on), Winer (Saint Pierre) and Winnock (Bordeaux).
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